InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,746.00
(
0.36%
)
Dow Jones
39,512.84
(
0.00%
)
Brent Oil
83.12
(
0.89%
)
Bitcoin
62,607.26
(
1.89%
)
Post# of 20689
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119621
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: indigokid post# 17994

Wednesday, 12/06/2017 4:41:46 PM

Wednesday, December 06, 2017 4:41:46 PM

Post# of 20689
My guess is: b). If so, MNTA’s justification could be that MYL’s approval for 40mg Copaxone renders 40mg Glatopa less consequential to MNTA’s business prospects than what is needed to trigger an 8-K.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!